MUSTANG BIO, INC.
Pharmaceutical Preparations
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
What MUSTANG BIO, INC. reports
Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Why the revenue box is blank
US GAAP has no one “total revenue” tag that every filer uses. A bank reports interest and dividend income separately from non-interest income; closed-end funds, blank-cheque companies and some property trusts report the same way; and a company that has not sold anything yet — a drug developer still in trials, for instance — files no revenue at all. Adding two differently defined income lines together would produce a number that appears in no filing, so we publish a revenue figure only where the filing tags one annual, US-dollar revenue fact we can point at. A blank here means no such tag, not that we failed to look.
Where the employee count comes from
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Insiders at MUSTANG BIO, INC.
Shares is what each person last reported holding here.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
David Jin
|
CFO | 286 | $155 | P Open-market purchase Dec 30, 2025 position reported |
Recent insider transactions
Of the 1 rows we hold, 1 are open-market purchases (P) and 0 open-market sales — the only codes we count as buying or selling.
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 30, 2025 | David Jin | P Open-market purchase | 247 | $0.96 | $237 | SEC filing ↗ |
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
What a Form 4 is
The report an officer, director or large shareholder must file after trading their own company’s stock.
Corporate ownership links — 1 filer holds a position
Who owns MUSTANG BIO, INC.
Each row is one filer naming this company.
Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.
Filers holding a position in MUSTANG BIO, INC.
| Owner | Reported role | Shares | Filed |
|---|---|---|---|
| Fortress Biotech, Inc. FBIO | TenPercentOwner | 536,577 |
See the full ownership map — every entity that files as an owner of a US public company.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Sources and technical notes
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: weighted average over the reporting period (us-gaap:WeightedAverageNumberOfSharesOutstandingBasic), taken from
MUSTANG BIO, INC.’s own filings and multiplied by our closing price.
≈ Not a single-day figure — treat this
market cap and its rank as approximate.
Full method.
What that share count means
this company did not tag a cover-page share count we could read, so the figure is the average number of shares outstanding across the whole reporting period rather than a count on any single day. If the company issued or bought back stock during the period, the true count today is higher or lower than this.
We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from MUSTANG BIO, INC.’s own SEC filings multiplied by the closing price we hold for the same stock.